Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Key Points: Low-dose hypomethylating agents are safe and effective in patients with lower-risk MDS and MDS/MPN. Decitabine was associated higher response rates compared with azacitidine, especially in patients with higher-risk features.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Thall, P. F., Simon, R. M., & Estey, E. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.296 · Cited by 131
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Platzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-10-844696 · Cited by 235
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Montalban‐Bravo, G. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 187
Self-citationCurrent and emerging strategies for management of myelodysplastic syndromes
Saygin, C., & Carraway, H. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100791 · Cited by 70
The Role of Epigenetics in the Development and Progression of Multiple Myeloma
Ismail, N. H., Mussa, A., Zakaria, N. A., Al-Khreisat, M. J., Zahidin, M. A., Ramli, N. N., Mohammad, S. N. N. A., Hassan, R., Mohd Noor, N. H., Iberahim, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112767 · Cited by 22
Metadata
- Authors
- Jabbour, E., Short, N. J., Montalban-Bravo, G., Huang, X., Bueso-Ramos, C., Qiao, W., Yang, H., Zhao, C., Kadia, T., Borthakur, G., Pemmaraju, N., Sasaki, K., Estrov, Z., Cortes, J., Ravandi, F., Alvarado, Y., Komrokji, R., Sekeres, M. A., Steensma, D. P., DeZern, A., Roboz, G., Kantarjian, H., & Garcia-Manero, G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-09-28
- Volume
- 130
- Issue
- 13
- Pages
- 1514-1522
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2742767772
- Cited by
- 182
- References
- 6
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. https://app.cochat.ai/papers/10.1182/blood-2017-06-788497
- The paper
- Jabbour, E., Short, N. J., Montalban-Bravo, G., Huang, X., Bueso-Ramos, C., Qiao, W., Yang, H., Zhao, C., Kadia, T., Borthakur, G., Pemmaraju, N., Sasaki, K., Estrov, Z., Cortes, J., Ravandi, F., Alvarado, Y., Komrokji, R., Sekeres, M. A., Steensma, D. P., . . . Garcia-Manero, G. (2017). Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. https://doi.org/10.1182/blood-2017-06-788497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.